ASLAN Pharmaceuticals Enters Licensing Deal With Zenyaku Kogyo For Development And Commercialization Of Eblasakimab In Japan; Co. Will Receive $15M In Upfront And Near-Term Payments And Up To $123.5M In Milestones
Portfolio Pulse from Bill Haddad
ASLAN Pharmaceuticals has entered a licensing deal with Zenyaku Kogyo for the development and commercialization of Eblasakimab in Japan. ASLAN will receive $15M in upfront and near-term payments and up to $123.5M in milestones.
June 22, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ASLAN Pharmaceuticals' licensing deal with Zenyaku Kogyo for Eblasakimab in Japan will bring in $15M upfront and up to $123.5M in milestones.
The licensing deal with Zenyaku Kogyo will provide ASLAN Pharmaceuticals with significant upfront and milestone payments, which will likely have a positive impact on the company's financial position and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100